2-hydroxy-3-(3,6,9-trioxadecyloxy)benzonitrile | 1037282-58-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-hydroxy-3-(3,6,9-trioxadecyloxy)benzonitrile
• 英文别名: 2-Hydroxy-3-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]benzonitrile
• CAS: 1037282-58-8
• 化学式: C₁₄H₁₉NO₅
• 分子量: 281.309
• InChiKey: OVBJLTGUAXTZSR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  20
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  80.9
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-hydroxy-3-(3,6,9-trioxadecyloxy)benzonitrile 、 2-甲基-D-半胱氨酸盐酸盐 在 碳酸氢钠 、 盐酸 、 水 作用下， 以 甲醇 为溶剂， 反应 72.0h， 以90%的产率得到(S)-2-(2-hydroxy-3-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)phenyl)-4-methyl-4,5-dihydrothiazole-4-carboxylic acid
  参考文献：
  名称：

  WO2008/115433

  摘要：

  公开号：
• 作为产物：
  描述：

  2,3-二羟基苯甲腈 、 对甲苯磺酸三缩乙二醇单甲醚酯 在 sodium hydride 作用下， 以 二甲基亚砜 为溶剂， 反应 25.0h， 以70%的产率得到2-hydroxy-3-(3,6,9-trioxadecyloxy)benzonitrile
  参考文献：
  名称：

  WO2008/115433

  摘要：

  公开号：

文献信息

• [EN] ORAL FORMULATIONS FOR TREATING METAL OVERLOAD<br/>[FR] FORMULATIONS ORALES POUR TRAITER UNE SURCHARGE EN MÉTAL
  申请人：FERROKIN BIOSCIENCES INC

  公开号：WO2013086312A1

  公开（公告）日：2013-06-13

  The present invention provides, among other things, effective oral formulations based on desazadesferrithiocin polyether (DADFT-PE) analogues, salts and polymorphs thereof, as well as their application for treatment of metal overload, in particular, iron overload, and associated diseases, disorders and conditions.

  本发明提供了一种基于去氧代脱铁异硫氰酸聚醚（DADFT-PE）类似物、盐和多晶形式的有效口服制剂，以及它们在治疗金属过载，特别是铁过载及相关疾病、障碍和病况中的应用。
• DESFERRITHIOCIN POLYETHER ANALOGUES
  申请人：Bergeron, JR. Raymond J.

  公开号：US20100093812A1

  公开（公告）日：2010-04-15

  A relatively non-toxic desazadesferrithiocin analog having the formula (I): wherein: R 1 , R 2 , R 4 and R 5 may be the same or different and may be H, straight or branched chain alkyl having up to 14 carbon atoms, e.g., methyl, ethyl, propyl and butyl, or arylalkyl wherein the aryl portion is hydrocarbyl and the alkyl portion is straight or branched chain, the arylalkyl group having up to 14 carbon atoms, R2 optionally being alkoxy having up to 14 carbon atoms; R 3 is [(CH 2 ) n —O] x —[(CH 2 ) n —O] y -alkyl; n is, independently, an integer from 1 to 8; x is an integer from 1 to 8; y is an integer from O to 8, and R 3 O may occupy any position on the phenyl ring except the 4-position, or a salt, hydrate or solvate thereof; and methods and compositions for treating the effects of trivalent metal, i.e., iron, overload.

  一种相对无毒的去除铁过载的治疗方法，使用化学式（I）的类去铁血红素衍生物，其中：R1、R2、R4和R5可以相同或不同，可以是氢，直链或支链烷基，碳数不超过14个，例如，甲基，乙基，丙基和丁基，或芳基烷基，其中芳基部分为烃基，烷基部分为直链或支链，芳基烷基的碳数不超过14个，R2可以选择为碳数不超过14个的烷氧基；R3为[(CH2)n-O]x-[( )n-O]y-烷基；n独立地为1到8的整数；x为1到8的整数；y为0到8的整数，R3O可以占据苯环上除4位以外的任何位置，或其盐，水合物或溶剂化物；以及治疗三价金属，即铁，过载的方法和组合物。
• ORAL FORMULATIONS FOR TREATING METAL OVERLOAD
  申请人：FerroKin BioSciences, Inc.

  公开号：US20130225645A1

  公开（公告）日：2013-08-29

  The present invention provides, among other things, effective oral formulations based on desazadesferrithiocin polyether (DADFT-PE) analogues, salts and polymorphs thereof, as well as their application for treatment of metal overload, in particular, iron overload, and associated diseases, disorders and conditions.

  本发明提供了基于去氮去硫铁聚醚（DADFT-PE）类似物、盐和多晶形式的有效口服制剂，以及它们用于治疗金属超载，特别是铁超载以及相关疾病、疾病和病状的应用。
• Design, Synthesis, and Testing of Non-Nephrotoxic Desazadesferrithiocin Polyether Analogues
  作者：Raymond J. Bergeron、Jan Wiegand、James S. McManis、Neelam Bharti、Shailendra Singh

  DOI：10.1021/jm800154m

  日期：2008.7

  A series of iron-clearing efficiencies (ICEs), ferrokinetics, and toxicity studies for (S)-2-(2,4-dihydroxyphenyl)4,5-dihydro-4-methyl-4-thiazolecarboxylic acid (deferitrin, 1), (S)-4,5-dihydro-2-[2-hydroxy-4-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylic acid (2), and (S)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyll-4-methyl-4-thiazolecarboxylic acid (3) are reported. The ICEs in rodents are shown to be dose-dependent and saturable for ligands 2 and 3 and superior to 1. Both polyether analogues in subcutaneous (sc) versus oral (po) administration in rodents and primates demonstrated excellent bioavailability. Finally, in a series of toxicity studies of ligands 1-3, the dosing regimen was shown to have a profound effect in animals treated with ligand 1. When ligand I was given at doses of 237 mu mol/kg/day twice a day (b.i.d.), there was serious proximal tubule damage versus 474,mu mol/kg/day once daily (s.i.d.). With 2 and 3, in iron-overloaded and/or non-iron-loaded rodents, kidney histopathologies remained normal.
• US8324397B2
  申请人：——

  公开号：US8324397B2

  公开（公告）日：2012-12-04